Wave Life Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Wave Life Sciences (Nasdaq: WVE) announced that Paul Bolno, MD, MBA, President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026 at 2:15 p.m. PT / 5:15 p.m. ET.
A live webcast will be available via the company's Investor Events page and a replay will be archived on the site for a limited time after the presentation.
Positive
- None.
Negative
- None.
News Market Reaction – WVE
In the Jan 5 session, WVE declined 5.96%, reflecting a notable negative market reaction. Argus tracked a peak move of +29.7% during that session. Argus tracked a trough of -5.5% from its starting point during tracking. Our momentum scanner triggered 37 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 09 | Equity offering | Negative | +15.1% | Upsized public offering of ordinary shares and pre-funded warrants. |
| Dec 08 | Equity offering | Negative | +147.3% | Proposed public offering to raise capital via shares and warrants. |
| Dec 08 | Clinical data | Positive | +147.3% | Positive interim Phase 1 INLIGHT results for obesity candidate WVE‑007. |
| Dec 07 | Data timing notice | Neutral | +147.3% | Notification of timing and access for upcoming WVE‑007 interim data. |
| Nov 10 | Earnings update | Positive | -10.3% | Q3 2025 results and pipeline update with extended cash runway. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Clinical trial updates have previously aligned with strong positive price reactions, while offerings and earnings updates often showed divergence, with shares sometimes rising on financing and falling on fundamentally positive updates.
Over the last few months, Wave Life Sciences reported several major events, including positive Phase 1 INLIGHT data for WVE‑007, multiple financing announcements totaling about $350M, and Q3 2025 results highlighting extended cash runway into 2Q 2027. Clinical news for WVE‑007 and obesity generated large positive moves, whereas the earnings update saw a negative reaction. Today’s conference appearance notice fits within an active period of data, financing, and investor outreach.
Jargon Translator
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Tuesday, January 13, 2026 at 2:15 p.m. PT / 5:15 p.m. ET.
A live webcast of the presentation can be accessed by visiting “Investor Events” on the Investors section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events. A replay of this presentation will be archived and available on the site for a limited time following the event.
About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s RNA medicines platform, PRISM®, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference, and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s diversified pipeline includes clinical programs in obesity, alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, and Huntington’s disease, as well as several preclinical programs utilizing the company’s broad RNA therapeutics toolkit. Driven by the calling to “Reimagine Possible,” Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X and LinkedIn.
Contact:
Kate Rausch
VP, Corporate Affairs and Investor Relations
+1 617-949-4827
Investors:
James Salierno
Director, Investor Relations
+1 617-949-4043
InvestorRelations@wavelifesci.com
Media:
Katie Sullivan
Senior Director, Corporate Communications
+1 617-949-2936
MediaRelations@wavelifesci.com
